Polar Asset Management Partners’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

Polar Asset Management Partners’s Portfolio BIOTW Stock Details BIOTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-620,800	Closed	-$39.7K	–	1327
2022 Q4	$39.7K	Hold	620,800	–	–	﹤0.01%	902
2022 Q3	$37K	Hold	620,800	–	–	﹤0.01%	1060
2022 Q2	$56K	Buy	620,800 +425,000	+217%	+$87.8K	﹤0.01%	1015
2022 Q1	$47K	Hold	195,800	–	–	﹤0.01%	1001
2021 Q4	$129K	Sell	195,800 -14,300	-7%	-$9.92K	﹤0.01%	1095
2021 Q3	$139K	Hold	210,100	–	–	﹤0.01%	1043
2021 Q2	$181K	Sell	210,100 -89,900	-30%	-$62.5K	﹤0.01%	949
2021 Q1	$180K	Buy	+300,000	New	+$212K	﹤0.01%	800

Polar Asset Management Partners's BIOTW Position: Q1 2023 in Review

Polar Asset Management Partners sold out of Biotech Acquisition Company Warrant (BIOTW) in Q1 2023, closing a stake of 620,800 shares — an estimated $39.7K sold.

Polar Asset Management Partners first reported a position in BIOTW in Q1 2021 and held it in 8 quarters. The position peaked at $181K in Q2 2021. 0 funds tracked by Wall St. Rank hold BIOTW as of Q1 2023.

Polar Asset Management Partners reported no remaining Biotech Acquisition Company Warrant position as of Q1 2023 after selling out during the quarter.
Polar Asset Management Partners sold 620,800 Biotech Acquisition Company Warrant shares in Q1 2023, an estimated $39.7K.
Polar Asset Management Partners first reported a position in Biotech Acquisition Company Warrant in Q1 2021 and held it in 8 quarters.
Polar Asset Management Partners's Biotech Acquisition Company Warrant position peaked at $181K in Q2 2021.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q1 2023.

Based on Polar Asset Management Partners's 13F filing for Q1 2023, filed 15 May 2023.